AI eyes colon polyps: can it spot the dangerous ones?
NCT ID NCT05754229
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This trial tests how accurately an AI system, called GI Genius, can identify which polyps found during a colonoscopy are adenomas, the type that can become cancer. About 395 adults undergoing screening, diagnostic, or surveillance colonoscopy will receive the AI-assisted procedure. Researchers will compare the AI's real-time characterization with the lab analysis of each removed polyp to measure its accuracy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AI-assisted colonoscopy using the GI Genius system, which helps detect and characterize polyps in real time
- What this could lead to
- If the AI proves accurate, it could help doctors identify harmless polyps during colonoscopy and avoid removing them, reducing unnecessary procedures.
- What could go wrong
- The AI may misclassify polyps, leading to missed adenomas or unnecessary removals. This is a quality assurance study, not a treatment trial, so it won't change outcomes directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
395 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for * Diagnostic colonoscopy due to symptoms/signs or * Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy) Exclusion Criteria: * Referral for removal of previous detected polyps * Emergency colonoscopy * Control colonoscopy due to inflammatory bowel disease (IBD)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal adenoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Holbæk Hospital
Holbæk, 4300, Denmark
-
Nykøbing Falster County Hospital
Nykøbing Falster, 4800, Denmark
-
Næstved Hospital
Næstved, 4700, Denmark
-
Zealand University Hospital
Køge, 4600, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?